What’s holding back aging biomarkers?
Despite growing excitement, most aging biomarkers today remain clinically irrelevant. This piece dives into the real bottleneck: our data. It maps the missing datasets, outlines what’s actually needed for biomarker validation, and proposes a path forward—designed to help researchers, biotech, and funders unlock real-world impact in aging therapeutics.

AAV gene therapy costs are rapidly dropping, echoing antibody manufacturing’s 15–20-year trajectory. Discover how scaled production, better safety data, and innovative delivery strategies open the door to treating common diseases like Parkinson’s, arthritis, and more.

The goals of the Longevity Journal Club are threefold:

1. Understand the history of longevity research and how the field developed over time

2. Be able to critically appraise past and current research

3. Develop taste to understand areas of novelty and/or where further research could be fruitful

In order to do this, landmark papers in the field were selected that explored the earliest history as well as the various subfields of longevity research. This list is not exhaustive of all areas. It covers areas or papers Martin Borch Jensen believes are some of the most interesting and important to understand for newcomers to the field. Over time, new papers and new subfields will be added to the curriculum. 

Designing the First Clinical Trial Targeting Aging
This piece outlines a conceptual framework for how a pivotal clinical trial targeting aging could be structured. It explores challenges in endpoint selection, regulatory alignment, and trial economics—ultimately proposing a multimorbidity-prevention design as the most viable path forward. A sample size calculator is included to help evaluate feasibility across different therapies. The goal: make aging drugs trialable, reimbursable, and real.

Norn Group’s mission is to maximize the probability that by 2060 we have interventions that will let a 60 year old live for another 60 years without a decline in health and function.
But how? Read about our approach, why aging should be treated as the root cause of chronic disease, why current tools are not enough, and how targeted investment in biomarkers, trial infrastructure, and interdisciplinary talent can accelerate progress of our Mission.